MTOR and melanoma: Optimization of mTOR inhibitor regimens is another key area for exploration, including determining whether intermittent dosing schedules (such as with rapamycin) can offer advantages over continuous administration and evaluating whether selective mTORC1 inhibition (e.g., rapamycin) or dual mTORC1/2 inhibitors (e.g., AZD2014) provide superior efficacy or tolerability in melanoma models.